title: Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia.
abstract: The aim of this study was to examine the effect of polymorphisms in the cytochrome P450 (CYP) 2C19 gene (CYP2C19) on the Helicobacter pylori eradication rate in Brazilian patients with functional dyspepsia. Adults diagnosed with functional dyspepsia based on the ROME III criteria and infected with H. pylori were recruited to this study. The patients were subjected to gastrointestinal endoscopy and the H. pylori status was defined when both urease test and histopathology results were negative or positive. The patients were treated with proton pump inhibitor-based triple therapy (omeprazole, amoxicillin, and clarithromycin). CYP2C19*2 and CYP2C19*3 were genotyped by polymerase chain reaction-restriction fragment length polymorphism. One hundred and forty-eight patients (81.8% women) with a mean (± SD) age of 46.1 (12.2) years were included in this study. Based on the CYP2C19 genotypes, the patients were classified as homozygous extensive metabolizer (HomEM; 67.6%), heterozygous extensive metabolizer (HetEM; 26.3%), or poor metabolizer (PM; 6.1%). The H. pylori eradication rates in patients with HomEM, HetEM, and PM were 85.0, 89.7, and 100.0% (P = 0.376), respectively. The included study population comprised a high frequency of patients carrying the HomEM genotype. Although the genotypes of CYP2C19 variants were not statistically significant, the results of this study suggest a possible effect of the PM genotype on the efficacy of H. pylori eradication.
authors.affiliation: Laboratório de Genética Molecular Humana, Universidade Luterana do Brasil, Canoas, RS, Brasil.
authors.forename: D D
authors.initials: DD
authors.lastname: Nabinger
authors.affiliation: Serviço de Gastroenterologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.
authors.forename: L E
authors.initials: LE
authors.lastname: Mazzoleni
authors.affiliation: Serviço de Gastroenterologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.
authors.forename: G B
authors.initials: GB
authors.lastname: Sander
authors.affiliation: Serviço de Gastroenterologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.
authors.forename: F
authors.initials: F
authors.lastname: Mazzoleni
authors.affiliation: Laboratório de Genética Molecular Humana, Universidade Luterana do Brasil, Canoas, RS, Brasil.
authors.forename: M C
authors.initials: MC
authors.lastname: Osório
authors.affiliation: Laboratório de Genética Molecular Humana, Universidade Luterana do Brasil, Canoas, RS, Brasil.
authors.forename: M G
authors.initials: MG
authors.lastname: Klein
authors.affiliation: Laboratório de Genética Molecular Humana, Universidade Luterana do Brasil, Canoas, RS, Brasil.
authors.forename: T F
authors.initials: TF
authors.lastname: Rech
authors.affiliation: Instituto de Ciências da Saúde, Universidade FEEVALE, Novo Hamburgo, RS, Brasil.
authors.forename: L
authors.initials: L
authors.lastname: Basso da Silva
authors.affiliation: Serviço de Gastroenterologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.
authors.forename: G S
authors.initials: GS
authors.lastname: de Moraes
authors.affiliation: Serviço de Gastroenterologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.
authors.forename: R A
authors.initials: RA
authors.lastname: Cristovam
authors.affiliation: Serviço de Gastroenterologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.
authors.forename: E F
authors.initials: EF
authors.lastname: Nardelli
authors.affiliation: Serviço de Gastroenterologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil.
authors.forename: C F M
authors.initials: CF
authors.lastname: Francesconi
authors.affiliation: Laboratório de Genética Molecular Humana, Universidade Luterana do Brasil, Canoas, RS, Brasil daniel.simon@ulbra.br.
authors.forename: D
authors.initials: D
authors.lastname: Simon
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage; D001938:Brazil; D017291:Clarithromycin / Q000008:administration & dosage; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D004415:Dyspepsia / Q000188:drug therapy / Q000235:genetics* / Q000382:microbiology; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005838:Genotype; D016481:Helicobacter Infections / Q000188:drug therapy / Q000235:genetics* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects / Q000235:genetics* / Q000472:pathogenicity; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide
chemical_list: D000658:Amoxicillin; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D017291:Clarithromycin; D009853:Omeprazole